Navigation Links
Jellyfish Protein Shows Potential to Help With Memory

BOSTON, Oct. 15 /PRNewswire/ -- Quincy Bioscience (Madison, WI) announces that Prevagen(R) (, a dietary supplement consisting of the jellyfish protein apoaequorin, has displayed great potential to improve memory in healthy human subjects tested. The Prevagen Memory Study included 56 participants that completed a 30-day open-label study (10 mg/day). The findings suggest that supplementation with apoaequorin, a well-known calcium-binding protein, might address the age-related deficits in memory that are often affiliated with decreasing calcium homeostasis.

Quincy Bioscience has been researching the jellyfish protein for the past twelve years and has had Prevagen in the marketplace for just over one year. Their research showed that 57% of the participants experienced overall memory improvement in 30 days. 66% of participants reported better word recall in conversation within 30 days and many participants showed memory improvement in as few as 8 days. Participants' ages averaged 56 years (20-78 yrs.) and 66% were female and 34% male. All participants were in good health. There were no dropouts from the study due to side effects.

"Too much calcium within a brain cell impairs its function and Prevagen works to regulate it," says Mark Underwood, co-founder of Quincy Bioscience. "Unfortunately, we lose our ability to regulate brain cell calcium as we age. At about forty, our brains produce fewer calcium-binding proteins. This causes calcium levels to rise throughout the nervous system. Neurons are flooded with dangerous levels of calcium and our brains slow down. We are excited to see these results."

"Apoaequorin, with its ability to bind to and lower calcium levels, can be used as a replacement for our own missing calcium-binding proteins and thereby slow age-related loss of cognitive function, memory, and alertness. Additional clinical trials are planned," added Underwood, "but this is a great first step. It shows that we are on the right track to address age-related memory issues."

The jellyfish protein is very similar to the calcium binding proteins found in the human nervous system which become depleted in age-related diseases like Alzheimer's. Data demonstrating the neuroprotective ability of this protein was first presented at the Society for Neuroscience meeting in 2006.

"Having strong science is the key to helping people that are interested in natural and alternative health products," added Mike Beaman, co-founder of Quincy Bioscience. "It is exciting that we can help the memory of others with Prevagen. There are many people that will benefit as the result of this important research."

Quincy Bioscience will be exhibiting during the Natural Products ExpoEast at the Boston Convention and Exhibition Center October 16th-18th. Representatives will be on hand in booth # 439 with literature and information detailing the research.

Quincy Bioscience ( is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms. Quincy Bioscience is developing health applications of the jellyfish protein apoaequorin for dietary supplement and pharmaceutical products. The company's first product, Prevagen (, was launched in the fall of 2007 and is intended to supplement the loss of critical calcium-binding proteins depleted in the normal course of healthy aging.

* These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

SOURCE Quincy Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
2. Researchers write protein nanoarrays using a fountain pen and electric fields
3. Protein Research Marketing Insights
4. Protein Sciences Announces Termination of Deal to Sell to Emergent BioSolutions
5. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
6. Incorrectly cleaved protein leads to schizophrenia
7. Not the protein, but its location in the cell, determines the onset of leukemia
8. Protein Sciences Responds to Emergent BioSolutions Lawsuit
9. Enhanced Protein Tomography(TM) Method for Rapid Epitope Determination
10. Large-scale community protein annotation -- WikiProteins
11. The Protein Tomography(TM) Award Now Published on Sidecs Homepage
Post Your Comments:
(Date:11/28/2015)... ... ... • Jeon Jin Bio Corp, a Korean Biotech venture company, has developed ... Bird Free, an oil-based, gel formula made from natural ... smell, taste and touch, enabling safe, effective avian control without toxic chemicals , ...
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):